Clinical Trials Browser

Phase 1/2 × Has results × LY-2157299 × Clear all

NCT02423343 2021-09-09

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

Phase 1/2 Completed

41 enrolled 21 charts

GastrointestinalOther solid neoplasmThoracic

Solid Tumor

NCT01373164 2018-05-16

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Phase 1/2 Completed

170 enrolled 25 charts

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms